Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Starling Bank mulling New York listing - FT

(Sharecast News) - Starling Bank is reportedly considering a listing in New York as part of its expansion plans in the US. The London-based fintech's chief financial officer Declan Ferguson told the Financial Times Starling was currently weighing a US listing, where it could potentially achieve a higher valuation.

"We continue to observe what is happening externally with our peers, and also what is happening on the global stage in terms of the UK versus US [stock markets]," he said.

When asked whether the company would be better suited on a US exchange, Ferguson said that Starling had not formed a "concrete view", and that the final decision over where any potential listing would take place was still "in flux".

He added cautioned that Starling was in no hurry to float. Last year, the bank's former interim chief executive John Mountain said that the fintech was "very committed" to a listing in London, which he described as the company's "natural home".

Ferguson, who has been at Starling since 2017, said that, while a New York listing might help boost its valuation, the company was first concentrating on expanding its US business.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.